HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Legend Biotech (NASDAQ:LEGN), with a maintained price target of $87.

April 23, 2024 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech's stock rating was reiterated as Buy by HC Wainwright & Co. with a price target of $87.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100